Search Results - "Timothy, Panella"

Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma by Ranganath, Harsha A, Panella, Timothy J

“…The CTLA-4 immune checkpoint inhibitor ipilimumab improves overall survival in metastatic melanoma. Its use in organ transplant recipients has not been studied…”
Get full text

349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) by Algazi, Alain, Smith, William, Panella, Timothy, Shin, Dong, Fjaellskog, Marie-Louise, Celebi, John, Drumheller, Alice, Campbell, Jean, Pierce, Robert, Guarino, Michael

“…BackgroundEfficacy of anti-PD-1 therapy is attributed to the presence of infiltrating antigen-specific CD8+ T-cells. Despite the success of anti-PD-1 therapy,…”
Get full text

Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase in Patients With Unresectable Malignant Mesothelioma by Mikulski, S. M.

Get full text

Metastasis of squamous cell carcinoma of the bladder to the heart: Case report and review of the literature by White, Wesley M., Waters, W. Bedford, Panella, Timothy J., Klein, Frederick A.

“…A 79-year-old woman with no previous history of genitourinary disease presented to an outside urologist with gross hematuria and irritative voiding symptoms…”
Get full text

Letter to the Editor: ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma by Alsharif, Omar, Panella, Timothy, Nodit, Laurentia, Hu, Mimi I

Get more information

Abstract OT-02-01: A longitudinal study assessing sexual dysfunction in postmenopausal women with breast cancer undergoing adjuvant treatment by Worth, Heidi, Panella, Timothy, Bell, Clayton, Rasnake, Mark, Roberson, Patricia, Lewis, Lauren

“…Abstract According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), Female Sexual Dysfunction is defined as a sexual problem…”
Get full text

First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study by Dudnichenko, Oleksandr, Penkov, Konstantin, McKean, Meredith, Mandalà, Mario, Kukushkina, Mariia, Panella, Timothy, Csőszi, Tibor, Gerletti, Paola, Thakur, Mahgull, Polli, Anna, di Pietro, Alessandra, Schadendorf, Dirk

“…BRAF inhibitors plus MEK inhibitors (BRAFi/MEKi) and immune checkpoint inhibitors (CPIs) are approved for BRAF V600-mutant advanced melanoma. Combinations of…”
Get full text

Abstract P3-23-04: A comprehensive, multidisciplinary approach to breast cancer treatment during the COVID-19 pandemic improves time to treatment by Orucevic, Amila, Hutson, Robin, Heidel, Robert, Lloyd, Jillian, Morin-Ducote, Garnetta, Lauro, Christine, Perkins, Ellen, Panella, Timothy, Duncan, Lisa, VanMeter, Stuart, Bell, John

“…Abstract A recently published study from the National COVID Cohort Collaborative (N3C) revealed that COVID-19 (CoV) positive status in cancer patients (pts)…”
Get full text

A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma by Panella, Timothy J., Thomas, Sajeve Samuel, McKean, Meredith, Margolin, Kim Allyson, Weight, Ryan Michael, Mani, Jayakumar, Patel, Shraddha, Desai, Priya, Salvati, Mark, Lowy, Israel, Fury, Matthew G., Gullo, Giuseppe

“…TPS9598 Background: Melanoma (Mel) accounts for the majority of skin cancer-related deaths. Most patients (pts) with a newly diagnosed Mel have resectable…”
Get full text

CemiplimAb-rwlc survivorship and epidemiology (CASE): A prospective study of safety and efficacy of cemiplimab in patients with advanced basal cell carcinoma in a real-world setting by Park, Soo J, Ellison, David, Weight, Ryan Michael, Homsi, Jade, Rabinowits, Guilherme, Ruiz, Emily S., Strasswimmer, John, Simmons, Josh David, Panella, Timothy J., Quek, Ruben GW, Ursino, Gregory, Pouliot, Jean-Francois, Khushalani, Nikhil I.

“…TPS9614 Background: Basal cell carcinoma (BCC) is the most common form of non-melanoma skin cancer in the United States. Surgical excision is the standard…”
Get full text

Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI) by Schadendorf, Dirk, Dummer, Reinhard, Robert, Caroline, Ribas, Antoni, Sullivan, Ryan J., Panella, Timothy J., McKean, Meredith, Santos, Edgardo S., Clancy, Jill S., Thakur, Mahgull Nazar, Polli, Anna, Di Pietro, Alessandra, Ascierto, Paolo Antonio

“…9531 Background: BRAF inhibitors (BRAFi) + MEK inhibitors (MEKi) (eg, enco + bini) and immune checkpoint inhibitors (CPIs) (eg, pembro) are approved for…”
Get full text

A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM) by Davar, Diwakar, Ikeguchi, Alexandra, Buchbinder, Elizabeth Iannotti, Shoushtari, Alexander Noor, Seedor, Rino S., Bernicker, Eric, Weiss, Sarah A., Daniels, Gregory A., Panella, Timothy J., Ryan, Hannah Frances, Goodall, Howard, Sullivan, Ryan J.

“…TPS9594 Background: Tebentafusp is a bispecific (gp100 x CD3) ImmTAC that can redirect T cells to target gp100+ melanoma cells. In a Phase (Ph) 3 trial,…”
Get full text

Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study by Bastasch, Michael, Panella, Timothy J, Kretzschmer, Shari L, Graham, Debbie, Mayo, Matt, Williamson, Stephen

“…More active agents are needed in the treatment of metastatic non-small cell lung cancer. Pyrazoloacridine (PZA) is a 9-methoxy acridine compound containing a…”
Get full text

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma by Schadendorf, Dirk, Dummer, Reinhard, Robert, Caroline, Ribas, Antoni, Sullivan, Ryan J, Panella, Timothy, McKean, Meredith, Santos, Edgardo S, Brill, Kimberli, Polli, Anna, Pietro, Alessandra di, Ascierto, Paolo A

“…Despite the significant progress in the treatment of unresectable or metastatic V600-mutant melanoma, there remains two primary treatment options: targeted…”
Get full text

Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) by Algazi, Alain Patrick, Shah, Dhaval, Smith, William, Panella, Timothy J., Shin, Dong Moon, Bruce, Justine Yang, Melhem, Ramzi, Campbell, Jean S., Abell, Lauren, Fjaellskog, Marie-Louise, Celebi, John K., Pierce, Robert Hamilton, Gramza, Ann Wild

“…Abstract only 6029 Background: The absence of infiltrating antigen-specific CD8+ T-cells at baseline is associated with low response rates to PD-1 blockade…”
Get full text

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women by Ferguson, N Lynn, Bell, John, Heidel, Robert, Lee, Solomon, Vanmeter, Stuart, Duncan, Lisa, Munsey, Barbara, Panella, Timothy, Orucevic, Amila

“…Estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) status are well-established prognostic markers in breast…”
Get more information

Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience by Orucevic, Amila, Chen, Jason, McLoughlin, James M, Heidel, Robert E, Panella, Timothy, Bell, John

“…We have previously demonstrated that TNM status and age were significant predictors of overall survival (OS) in our study population of Caucasian patients with…”
Get more information

Abstract PD1-04: Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC) by Mariotti, Veronica, Tang, Shou-Ching, Dillon, Patrick, Montero, Alberto, Poklepovic, Andrew, Melin, Susan, Nuhad, Ibrahim, Nikolinakos, Petros, Kennedy, Eugene, Han, Hyo, Ismail-Khan, Roohi, Bruetman, Daniel, Danciu, Oana, Gilman, Paul, Karaszewska, Boguslawa, Lesniewski-Kmak, Krzysztof, Panella, Timothy, Patel, Dhimant, Suszko-Kazarnowicz, Malgorzata, Volterra, Fabio, Soliman, Hatem

“…Abstract Background: IDO1 is a mediator of tumor immune suppression through alteration of tryptophan metabolism. Indoximod (1-methyl-tryptophan) is an IDO1…”
Get full text

Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma by Schadendorf, Dirk, Dummer, Reinhard, Robert, Caroline, Ribas, Antoni, Sullivan, Ryan J., Panella, Timothy, McKean, Meredith, Santos, Edgardo S., Clancy, Jill, Polli, Anna, di Pietro, Alessandra, Ascierto, Paolo A.

“…Abstract Background BRAF V600 mutations are frequently found in metastatic melanoma. This mutation constitutively activates the MAPK pathway, which leads to…”
Get full text

A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma by Edenfield, William Jeffery, Becerra, Carlos, Braiteh, Fadi S., Spira, Alexander I., Sullivan, Ryan J., Panella, Timothy J., Li, Wei, Huang, Janet, Li, Youzhi, Flaherty, Keith, Hitron, Matthew, Li, Chiang

“…Abstract only 9553 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription…”
Get full text